Immunome Beheer

Beheer criteriumcontroles 1/4

De CEO Immunome is Clay Siegall, benoemd in Oct2023, heeft een ambtstermijn van 1.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.65M, bestaande uit 1% salaris en 99% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.69% van de aandelen van het bedrijf, ter waarde $ 4.82M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.1 jaar en 3.4 jaar.

Belangrijke informatie

Clay Siegall

Algemeen directeur

US$15.6m

Totale compensatie

Percentage CEO-salaris	1.0%
Dienstverband CEO	1.1yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	1.1yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Clay Siegall's beloning veranderd ten opzichte van Immunome's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$305m
Jun 30 2024	n/a	n/a	-US$263m
Mar 31 2024	n/a	n/a	-US$232m
Dec 31 2023	US$16m	US$163k	-US$107m

Compensatie versus markt: De totale vergoeding ($USD 15.65M ) Clay } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.20M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Clay te vergelijken met de prestaties van het bedrijf.

CEO

Clay Siegall (63 yo)

1.1yrs

Tenure

US$15,648,944

Compensatie

Dr. Clay B. Siegall, Ph D., serves as Independent Chairman since December 13, 2023 at Tourmaline Bio, Inc. He served as Chief Executive Officer & President of Morph Immune, Inc. from March 2023 until Octob...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Clay Siegall	President	1.1yrs	US$15.65m	0.69% $ 4.8m
Jack Higgins	Chief Scientific Officer	1.1yrs	US$2.17m	0.022% $ 155.5k
Robert Lechleider	Chief Medical Officer	1.1yrs	US$3.22m	geen gegevens
Max Rosett	Executive VP of Operations	1.1yrs	geen gegevens	0.079% $ 545.8k
Philip Tsai	Chief Technical Officer	no data	geen gegevens	geen gegevens
Sandra Stoneman	Chief Legal Officer	4.1yrs	US$1.64m	0.0092% $ 63.8k
Bruce Turner	Chief Strategy Officer	1.1yrs	geen gegevens	0.070% $ 486.3k
Kinney Horn	Chief Business Officer	less than a year	geen gegevens	geen gegevens
Roee Shahar	Executive Vice President of Commercial	less than a year	geen gegevens	geen gegevens

1.1yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IMNM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Clay Siegall	President	1.1yrs	US$15.65m	0.69% $ 4.8m
Louis Weiner	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Philip Wagenheim	Director	6.9yrs	US$59.23k	0.65% $ 4.5m
George Prendergast	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Isaac Barchas	Lead Independent Director	1.1yrs	US$296.59k	0.0086% $ 59.7k
James Boylan	Independent Director	1.1yrs	US$294.75k	0% $ 0
Andrew Badley	Member of COVID-19 Advisory Board	3.4yrs	geen gegevens	geen gegevens
Carol Schafer	Independent Director	less than a year	geen gegevens	0% $ 0
William Strohl	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jeffrey Henderson	Member of COVID-19 Advisory Board	4.2yrs	geen gegevens	geen gegevens
Shmuel Shoham	Member of COVID-19 Advisory Board	4.2yrs	geen gegevens	geen gegevens
Susan Weiss	Member of COVID-19 Advisory Board	4.2yrs	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IMNM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Immunome Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024

Consensus revenue estimates increase by 21%, EPS downgraded

Price target decreased by 8.7% to US$30.60

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell 3000E Growth Index

Director recently bought US$248k worth of stock

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

Immunome launches $27M private placement

Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?

Immunome, Inc. Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

New 90-day high: US$39.01

Abzena Selects Immunome, Inc.’s Partner Research Organization for IMM-BCP-01

New 90-day high: US$20.24

Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares